Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon

被引:0
|
作者
Schuette, W. [1 ]
Thomas, M. [2 ]
Eberhardt, W. [3 ]
Zirrgiebel, U. [4 ]
Radke, S. [5 ]
Dietel, M. [6 ]
机构
[1] Krankenhaus Martha Maria, Halle, Saale, Germany
[2] Univ Klinikum, Thoraxklin, Heidelberg, Germany
[3] Univ Klinikum, Med Onkol, Essen, Germany
[4] iOMEDICO AG, Freiburg, Germany
[5] AstraZeneca GmbH, Wedel, Germany
[6] Humboldt Univ, Pathol Inst, D-10099 Berlin, Germany
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
0341
引用
收藏
页码:120 / 120
页数:1
相关论文
共 41 条
  • [41] Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials
    Raimondi, A.
    Morano, F.
    Trarbach, T.
    Karthaus, M.
    Lonardi, S.
    Fruehauf, S.
    Cremolini, C.
    Graeven, U.
    Bittoni, A.
    Mueller, L.
    Bianchi, A. Sartore
    Aranda, E.
    Boige, V.
    Stintzing, S.
    Di Bartolomeo, M.
    Koenig, A.
    Pietrantonio, F.
    Modest, D.
    ANNALS OF ONCOLOGY, 2022, 33 : S366 - S366